PMC:7195088 / 65192-65411 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T89792","span":{"begin":151,"end":168},"obj":"Chemical"},{"id":"T91905","span":{"begin":158,"end":168},"obj":"Chemical"}],"attributes":[{"id":"A80616","pred":"chebi_id","subj":"T89792","obj":"http://purl.obolibrary.org/obo/CHEBI_23924"},{"id":"A25044","pred":"chebi_id","subj":"T91905","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"In the absence of clinical studies, we suggest that also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) should be preferentially administered within RCT."}

{"project":"LitCovid-sentences","denotations":[{"id":"T464","span":{"begin":0,"end":219},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In the absence of clinical studies, we suggest that also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) should be preferentially administered within RCT."}